Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure
Source: Abbott.com - Category: Pharmaceuticals Source Type: news
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Heart | Heart Failure | Pharmaceuticals | Study